Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10962MR)

This product GTTS-WQ10962MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10962MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14133MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ828MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ7636MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ7824MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ13226MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ2493MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ4489MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ6743MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 992
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW